Â鶹ӳ»­

Cancer treatment is increasingly tailored to the unique genetic makeup of each patient¡¯s tumor. At the 2026 American Society for Clinical Oncology (ASCO) Annual Meeting, UT MD Anderson clinicians and researchers are showcasing breakthrough therapies targeting specific mutations and/or rare subsets of cancer, offering new hope for patients with historically hard-to-treat cancers.

Sharing our researchers¡¯ findings and ideas at conferences...